RESEARCH

Effects of SARS-CoV-2 infections in patients with cancer on mortality, ICU admission and incidence: a systematic review with meta-analysis involving 709,908 participants and 31,732 cancer patients

Mehmet Emin Arayici[1] · Nazlican Kipcak[2] · Ufuktan Kayacik[3] · Cansu Kelbat[2] · Deniz Keskin[2] ·
Muhammed Emin Kilicarslan[2] · Ahmet Veli Kilinc[2] · Sumeyye Kirgoz[2] · Anil Kirilmaz[2] ·
Melih Alihan Kizilkaya[2] · Irem Gaye Kizmaz[2] · Enes Berkin Kocak[2] · Enver Kochan[2] · Begum Kocpinar[2] ·
Fatmanur Kordon[2] · Batuhan Kurt[2] · Hulya Ellidokuz[3,4]

Abstract

Background Cancer patients constitute one of the highest-risk patient groups during the COVID-19 pandemic. In this study, it was aimed to perform a systematic review and meta-analysis to determine both the incidence and ICU (Intensive Care Unit) admission rates and mortality in SARS-CoV-2 infected cancer patients.

Methods The PRISMA guidelines were closely followed during the design, analysis, and reporting of this systematic review and meta-analysis. A comprehensive literature search was performed for the published papers in PubMed/Medline, Scopus, medRxiv, Embase, and Web of Science (WoS) databases. SARS-CoV-2 infection pooled incidence in the cancer populations and the risk ratio (RR) of ICU admission rates/mortality in cancer and non-cancer groups, with 95% confidence intervals (CIs), were calculated using the random-effects model.

Results A total of 58 studies, involving 709,908 participants and 31,732 cancer patients, were included in this study. The incidence in cancer patients was calculated as 8% (95% CI: 8–9%). Analysis results showed that mortality and ICU admission rate was significantly higher in patients with cancer (RR = 2.26, 95% CI: 1.94–2.62, $P < 0.001$; RR = 1.45, 95% CI: 1.28–1.64, $p < 0.001$, respectively).

Conclusion As a result, cancer was an important comorbidity and risk factor for all SARS-CoV-2 infected patients. This infection could result in severe and even fatal events in cancer patients. Cancer is associated with a poor prognosis in the COVID-19 pandemic. Cancer patients should be assessed more sensitively in the COVID-19 outbreak.

Keywords SARS-CoV-2 · Cancer · ICU admission · Mortality

Introduction

The COVID-19 outbreak caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which started with a case detected in China on 12 December 2019, was declared as a pandemic by the World Health Organization (WHO) on 11 March 2020 (WHO 2022, 2021; Rothe et al. 2020; Lu et al. 2020; Ge et al. 2020; Sung et al. 2021; Zhang et al. 2020). Currently (May 1, 2020), WHO reported there are 500 million confirmed cases worldwide, with over 6

million deaths documented (WHO 2022). One of the most important problems caused by pandemics is the difficulty in the management of chronic diseases, the frequency of which is increasing with the prolongation of life expectancy in today's world. Today, cancer constitutes a very important subset of chronic diseases. According to the GLOBOCAN (Global Cancer Observatory), in 2040, there will be 9.5 million new cancer cases globally and approximately 6.2 million new cancer-related deaths (GLOBOCAN 2022). It is obvious that the fight against this disease, which is currently very difficult to manage, requires the participation of many branches, and is quite deadly, has become even more difficult during the COVID-19 outbreak. But cancer and cancer-related deaths are just as important as the COVID-19 pandemic (Sung et al. 2021). This reveals the

✉ Mehmet Emin Arayici
mehmet.e.arayici@gmail.com

Extended author information available on the last page of the article

need to continue follow-up and treatment of patients even throughout the pandemic. Studies on COVID-19 revealed that advanced age and the presence of several comorbidities in patients result in a more severe COVID-19 clinical tableau and increased mortality (Zhang et al. 2020).

Cancer patients constitute the highest risk patient group during the pandemic due to both underlying diseases, most cancers occur at advanced age, and many chronic diseases increase with age (Rothe et al. 2020; Lu et al. 2020; Ge et al. 2020; Sung et al. 2021; Zhang et al. 2020). The majority of SARS-CoV-2 infected patients experience mild to moderate respiratory symptoms; however, 13.8 percent of COVID-19 patients have severe symptoms, which can lead to multiple organ failure or death (Tian et al. 2020; Pascarella et al. 2020; Li et al. 2020a, b; Jin et al. 2020). According to recent research, SARS-CoV-2 infected individuals with comorbidities, such as endocrinopathies, chronic respiratory, renal, or chronic neurological disease, heart illness and cancer, had a worse prognosis (Jin et al. 2020; Espinosa et al. 2020; Chow et al. 2020; Liang et al. 2020; Wu and McGoogan, 2020).

Current studies have highlighted that cancer enhances sensitivity to SARS-CoV-2 infection and is a risk factor for worse clinical outcomes in SARS-CoV-2 infected patients (Gao et al. 2020; Giannakoulis et al. 2020; Dai et al. 2020; Ma et al. 2020). In a meta-analysis conducted by Giannakoulis et al. (2020), which included a total of 32 studies, on 46,499 SARS-CoV-2 infected patients with malignancy, it was reported that all-cause mortality increased in patients with cancer (RR = 1.66, 95% CI: 1.33–2.07, $p < 0.001$). Similarly, in another meta-analysis that included a total of 63,019 participants, it was concluded that mortality was higher in populations with cancer (RR = 1.80, 95% CI: 1.38–2.35, $p < 0.001$) (Yang et al. 2021). However, current studies had a relatively small sample size for COVID-19. New studies are emerging on this subject day by day. Therefore, the incidence, mortality and ICU admission rate in SARS-CoV-2 infected cancer patients should be calculated in larger samples and wide geographies. The purpose of this study was to perform a systematic review and meta-analysis involving a total of 709,908 participants from 4 continents and 16 countries (Brazil, USA, Sweden, Iran, Spain, Portugal, Switzerland, Turkey, Korea, Ireland, Nigeria, UK, Japan, Italy, People's Republic of China, and India) to determine both the incidence, ICU admission rate and mortality in SARS-CoV-2 infected cancer patients.

Material and methods

Literature search and search strategy

The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) reporting guidelines were closely followed during the reporting, design, and analysis of this systematic review and meta-analysis (Liberati et al. 2009). Between March and April 11 (2022), a comprehensive literature searches were conducted for the published papers in PubMed/Medline, Scopus, medRxiv, Embase, and Web of Science (WoS) databases, and an update was performed on April 29 for this search. Related major factors were considered for the search query lines when choosing the keywords: "COVID-19", "clinical characteristics", "coronavirus", "2019-nCoV", "tumour", "SARS-CoV-2", "cancer", "malignancy", "outcomes", and "neoplasm". The related keywords were combined using Medical Subject Headings (MeSH) and text terms, and the Boolean operators AND/OR were used to integrate the keywords. The search strategy was developed in the PubMed, Scopus and WoS databases and applied to other databases (medRxiv, Embase). Search strategies in the related literature are available in Supplemental Table S1. Relevant studies that could be included in the meta-analysis were downloaded from related databases. Afterward, these studies were transferred to Mendeley data management program for data evaluation and analysis.

Study selection and inclusion/exclusion criteria

Original research (case–control or cohort) published about the effect of SARS-CoV-2 infection on cancer from the beginning of the pandemic to April 29th were included in this study. Original studies that were published in the English language were researched, and no other types of paper were examined. In addition, studies covering the following criteria listed below were included in this research: (i) determination of patients in the study as SARS-CoV-2 through clinical/laboratory diagnosis; (ii) the research includes information on the number of cases or deaths or ICU (Intensive Care Unit) admission of participants with and without cancer in populations infected with SARS-CoV-2. Exclusion criteria: (i) reviews, guidelines, opinions, or other non-original data publications; (ii) projects and clinical trials that were incomplete; and (iii) no clinical evidence from animal and laboratory studies.

PICOS:

1. Population: "SARS-CoV-2 infected cancer and non-cancer patients".

2. Intervention: "Cancer".

3. Comparison: "Non-cancer".

4. Outcomes: (i) "SARS-CoV-2 infection risk in patients with cancer"; (ii) "COVID-19 severity risk, including: ICU admission/mortality risk".

5. Study: "Cohort or case-control studies".

Data extraction, acquisition, and quality assessment

Papers were initially scanned based on the title and abstract in related database, and the full text of the appropriate papers were examined. The article titles and abstracts, and any differences amongst co-authors regarding which papers were eligible and which were not were handled using Delphi consensus criteria were examined by two independent authors (MEA and HE) (Verhagen et al. 1998), and the data was extracted into a pre-defined spreadsheet created using Microsoft Excel®. COVID-19 infection incidence, ICU admission, and mortality in cancer patients were separated into three groups and their risks were evaluated. Location, population, type of study, sex, number of patients with cancer and without cancer, ICU admission and mortality in patients with cancer and without cancer, with median age (if given) were also extracted into the same Excel file, in addition to the three key outcomes indicated above. To overcome data limitations-in case of missing data or doubt-the corresponding author(s) of the articles were contacted via email to obtain more details. Prepared data were cross-checked by two investigators via a standard spreadsheet to reach consensus. The Newcastle-Ottawa quality rating scale (NOS) was applied to all studies to evaluate the quality of the articles (Stang 2010).

Statistical analysis

Forest plots were utilized to compute and graphically illustrate the risk ratio (RR) with 95% confidence interval (CI) of COVID-19 infection incidence, ICU admission and mortality rates in the cancer and non-cancer groups, and to summarize them. All research that reported SARS-CoV-2 infection incidence, mortality and/or ICU admission rates in cancer patients as an outcome were evaluated in primary and secondary meta-analyses. Sensitivity analysis -all studies were excluded from analysis separately- was performed to test the reliability of the study results. Mortality and ICU admission rate results in Europe, America and Asia were included in the subgroup analyses. I^2 statistics and Cochran's Q test were used to quantified between-study heterogeneity in all meta-analyses. A ratio of more than 50% in I^2 statistics and a $p \leq 0.05$ in Cochran's Q test revealed that significant heterogeneity (Higgins et al. 2003). If the findings were heterogeneous, the analysis was carried out using random-effect models. Non-heterogeneous findings were calculated using fixed-effects models. For each significant outcome in our research, Egger's linear regression test and funnel plots were utilized to examine the possibility of publication bias. Furthermore, NOS risk assessment method was used to evaluate the risk of bias in the included studies (Stang 2010). For each study, this instrument assigns a maximum score of nine in three categories: "selection", "comparability", and "outcome". The statistical significance level was determined as a 2-sided $p < 0.05$. The Review Manager (v.5.4) (RevMan, 2020), ProMeta3® (Prometa-3, 2015) and Jamovi (version 2.3.3) (Jamovi, 2021) software were used for all the analyses.

Results

In the initial search, a total of 8806 articles were found, with 1357 in Web of Science, 2346 in PubMed, 1689 in Embase, 2956 in Scopus, and 458 in medRxiv databases. After a preliminary review and the elimination of duplicates, 5328 papers were screened and chosen for further evaluation. A total of 58 studies (Adejumo et al. 2021; Akhtar et al. 2021; Alpert et al. 2021; Arslan et al. 2021; Azarkar et al. 2021; Baker et al. 2021; Benelli et al. 2020; Bennett et al. 2021; Bergman et al. 2021; Bernard et al. 2021; Bhargava et al. 2021; Borobia et al. 2020; Pinto et al. 2020; Chai et al. 2021; Fu et al. 2021; Chudasama et al. 2021; Costa et al. 2021; Duanmu et al. 2020; Gold et al. 2020; Görgülü et al. 2020; Goyal et al. 2020; Gude-Sampedro et al. 2021; Guo et al. 2021; Joharatnam-Hogan et al. 2020; Katkat et al. 2021; Kim et al. 2021; Kokturk et al. 2021; Liang et al. 2021; Sun et al. 2021; Cavanna et al. 2020; Lunski et al. 2021; Martinot et al. 2021; Mirgh et al. 2021; Miyashita et al. 2020; Nakamura et al. 2021; Nikpouraghdam et al. 2020; Panda et al. 2022; Péron et al. 2021; Poli et al. 2022; Li et al. 2020a, b; Reddy et al. 2021; Regina et al. 2020; Ricoca-Peixoto et al. 2020; Giorgi-Rossi et al. 2020; Rugge et al. 2020; Erdal et al. 2021; Sami et al. 2020; Santorelli et al. 2021; Pérez-Segura et al. 2021; Serraino et al. 2021; Shahidsales et al. 2021; Sorouri et al. 2020; Stroppa et al. 2020; Tehrani et al. 2021; Vergara et al. 2021; Vila-Corcoles et al. 2021; Zhang et al. 2021; Zhou et al. 2021) (30 in Europe, 16 in Asia, 11 in America, and 1 in Africa) and 709,908 participants (31,732 cancer patients) were included in this systematic review and meta-analysis after applying the inclusion/exclusion criteria. A flow diagram demonstrating the selection process is available in Fig. 1, and the major parameters of the included studies are presented in Table 1. The quality scores of the included studies ranged from 6 to 9. The quality risk assessment of the relevant articles is shown in Supplementary Table S2. Furthermore, a bubble chart showing the distribution of studies by years is visually presented in Fig. S7.

Cancer incidence in SARS-CoV-2 infected patients

Data were analyzed from a total of 55 studies (Adejumo et al. 2021; Akhtar et al. 2021; Alpert et al. 2021; Arslan et al. 2021; Azarkar et al. 2021; Baker et al. 2021; Benelli et al. 2020; Bennett et al. 2021; Bergman et al. 2021; Bernard et al. 2021;

Fig. 1 PRISMA flow diagram of the study collection process

Bhargava et al. 2021; Borobia et al. 2020; Pinto et al. 2020; Chai et al. 2021; Fu et al. 2021; Chudasama et al. 2021; Costa et al. 2021; Duanmu et al. 2020; Gold et al. 2020; Görgülü and Duyan, 2020; Goyal et al. 2020; Gude-Sampedro et al. 2021; Guo et al. 2021; Katkat et al. 2021; Kim et al. 2021; Kokturk et al. 2021; Liang et al. 2021; Sun et al. 2021; Cavanna et al. 2020; Lunski et al. 2021; Martinot et al. 2021; Mirgh et al. 2021; Miyashita et al. 2020; Nakamura et al. 2021; Nikpour-aghdam et al. 2020; Panda et al. 2022; Péron et al. 2021; Poli et al. 2022; Li et al. 2020a, b; Reddy et al. 2021; Regina et al. 2020; Giorgi Rossi et al., 2020; Rugge et al. 2020; Erdal et al. 2021; Sami et al. 2020; Santorelli et al. 2021; Pérez-Segura et al. 2021; Serraino et al. 2021; Shahidsales et al. 2021; Soro-uri et al. 2020; Tehrani et al. 2021; Vergara et al. 2021; Vila-Corcoles et al. 2021; Zhang et al. 2021; Zhou et al. 2021) on the incidence of cancer in SARS-CoV-2 infected participants (689,462 total participants, 31,066 with cancer). The pooled incidence of cancer in SARS-CoV-2 infected patients is presented in Fig. 2. The pooled ES of incidence in cancer patients was calculated as 8% (95% CI: 8–9%). The cancer incidence in SARS-CoV-2 infected patients was higher than the global cancer incidence (approximately 0.2%) (Bray et al. 2018). The incidence differences between countries were also examined. Among the included studies, the highest incidence was in France (16.912%, 5939/89,952); the lowest incidence was found in Nigeria and Brazil (0.024%, 7406/322,816; 0.004%, 14/2848) (Supplementary Table S3). There was no significant publication bias in the analysis results ($P > 0.05$) (Supplementary Fig. S2). In our analysis, a significant level of heterogeneity was determined among the studies (df = 54, $I^2 = 99\%$, $p < 0.001$). Sensitivity analyzes were performed by extracting each study separately. No significant change was observed in the analysis results. Thus, the robustness of the analysis results was confirmed by sensitivity analysis.

## Mortality in SARS-CoV-2 infected cancer and non-cancer patients

A total of 42 studies (Akhtar et al. 2021; Alpert et al. 2021; Arslan et al. 2021; Azarkar et al. 2021; Baker et al.

Table 1 Patient characteristics of included studies in qualitative and quantitative synthesis

Author	Country	Type of study	Sex (Male)	Median age	Cancer patients	Total patients
Adejumo et al. (2021)	Nigeria	R. cohort	1872	60	14	2848
Akhtar et al. (2021)	UK	R. cohort	169	NA	51	293
Alpert et al. (2020)	USA	R. cohort	2907	66.5	421	5556
Arslan et al. (2021)	Turkey	R. cohort	374	52	41	713
Azarkar et al. (2021)	Iran	R. cohort	207	45	11	364
Baker et al. (2021)	UK	R. cohort	173	75	33	316
Benelli et al. (2020)	Italy	R. cohort	359	70.5	33	411
Bennett et al. (2021)	Ireland	R. cohort	8636	NA	747	19,789
Bergman et al. (2021)	Sweden	R. case-control	26,808	NA	5515	68,575
Bernard et al. (2021)	France	R. cohort	NA	NA	5722	89,051
Bhargava et al. (2021)	USA	R. cohort	294	64.4	46	565
Borobia et al. (2020)	Spain	R. cohort	1074	61	385	2226
Pinto et al. (2020)	Italy	R. cohort	733	71.7	138	1226
Chai et al. (2021)	China	R. cohort	246	65	166	498
Fu et al. (2021)	USA	R. Case-control	2438	71	233	4186
Chudasama et al. (2021)	UK	R. cohort	981	NA	179	1706
Costa et al. (2021)	Brazil	R. cohort	181,419	NA	7406	322,816
Duanmu et al. (2020)	USA	R. cohort	56	45	3	100
Gold et al. (2020)	USA	R. cohort	151	60	12	305
Gorgulu et al. (2020)	Turkey	R. cohort	278	74.4	75	483
Goyal et al. (2020)	USA	R. cohort	238	62.2	23	393
Gude-Sampedro et al. (2021)	Spain	R. cohort	4172	58	238	10,454
Guo et al. (2021)	China	R. cohort	3827	55	277	7926
Joharatnam-Hogan et al. (2020)	UK	R. case-control	80	NA	30	120
Katkat et al. (2021)	Turkey	R. cohort	270	NA	34	508
Kim et al. (2021)	Korea	R. cohort	3095	47	569	7590
Kokturk et al. (2021)	Turkey	R. cohort	850	NA	76	1500
Liang et al. (2021)	China	R. cohort	NA	65	109	3060
Sun et al. (2021)	USA	R. cohort	137	56	67	323
Cavanna et al. (2020)	Italy	R. cohort	NA	71	51	973
Lunski et al. (2021)	USA	R. cohort	2013	NA	312	5145
Martinot et al. (2021)	France	R. cohort	346	71.09	109	600
Mirgh et al. (2021)	India	R. cohort	126	43	109	200
Miyashita et al. (2020)	USA	R. cohort	NA	NA	334	5688
Nakamura et al. (2020)	Japan	R. cohort	22	74.5	32	235
Nikpouraghdam et al. (2020)	Iran	R. cohort	1955	56	17	2964
Panda et al. (2022)	India/China	R. cohort	279	37	10	420
Péron et al. (2021)	France	R. case-control	143	76.5	108	301
Poli et al. (2021)	Italy	R. cohort	653	71	141	1091
Li et al. (2020a, b)	China	R. cohort	934	59	65	1859
Reddy et al. (2021)	India	R. cohort	NA	40	23	4494
Regina et al. (2020)	Swiss	R. cohort	120	70.0	26	200
Ricoca Peixoto et al. (2020)	Portugal	R. cohort	8370	NA	611	20,270
Rossi et al. (2021)	Italy	R. cohort	1328	63.2	301	2653
Rugge et al. (2020)	Italy	R. cohort	4529	NA	723	9275
Erdal et al. (2021)	Turkey	R. cohort	NA	62	71	4489
Sami et al. (2020)	Iran	R. cohort	299	56.6	15	490
Santorelli et al. (2021)	UK	R. cohort	329	NA	47	582
Segura et al. (2021)	Spain	R. cohort	NA	75	770	5838
Serraino et al. (2021)	Italy	R. cohort	19,328	NA	3098	41,366

Table 1 (continued)

Author	Country	Type of study	Sex (Male)	Median age	Cancer patients	Total patients
Shahidsales et al. (2021)	Iran	R. case-control	111	59.6	92	185
Sorouri et al. (2020)	Iran	R. case-control	91	NA	53	159
Stroppa et al. (2020)	Italy	R. case-control	NA	NA	25	56
Tehrani et al. (2021)	USA	R. cohort	4991	60.4	892	8222
Vergara et al. (2021)	Italy	R. cohort	710	71.1	49	1049
Vila-Corcoles et al. (2021)	Spain	R. cohort	235	NA	67	536
Zhang et al. (2022)	China	R. cohort	17,662	59	824	36,358
Zhou et al. (2021)	China	R. case-control	171	66	103	309
Total					31,732	709,908

Fig. 2 Forest plot illustrating the incidence of patients with cancer in all SARS-CoV-2 infected participants

2021; Benelli et al. 2020; Bennett et al. 2021; Bernard et al. 2021; Bhargava et al. 2021; Borobia et al. 2020; Pinto et al. 2020; Chai et al. 2021; Fu et al. 2021; Gude-Sampedro et al. 2021; Guo et al. 2021; Joharatnam-Hogan et al. 2020; Katkat et al. 2021; Kim et al. 2021; Kokturk et al. 2021; Liang et al. 2021; Sun et al. 2021; Lunski et al. 2021; Martinot et al. 2021; Mirgh et al. 2021; Miyashita et al. 2020; Péron et al. 2021; Poli et al. 2022; Li et al. 2020a, b; Reddy et al. 2021; Ricoca Peixoto et al. 2020; Giorgi-Rossi et al. 2020; Rugge et al. 2020; Erdal et al. 2021; Pérez-Segura et al. 2021; Serraino et al. 2021; Shahidsales et al. 2021; Sorouri et al. 2020; Stroppa et al. 2020; Vergara et al. 2021; Vila-Corcoles et al. 2021; Zhang et al. 2021; Zhou et al. 2021) were included in the analysis to compare the mortality rates of cancer and non-cancer patients infected with SARS-CoV-2. There were a total of 557,053 participants, of whom 21,599 were cancer patients. According to the analysis results, cancer is a serious risk factor for mortality among patients infected with SARS-CoV-2 (RR = 2.26, 95% CI: 1.94–2.62, $P < 0.001$, Fig. 3). Mortality rates between continents were also evaluated as subgroup analysis and presented in Fig. 4. Mortality in cancer patients infected with SARS-CoV-2 varies between continents, with the highest mortality rate

Study or Subgroup	Cancer Events	Cancer Total	Non-Cancer Events	Non-Cancer Total	Weight	Risk Ratio M–H, Random, 95% CI
Akhtar et al 2021	30	51	103	242	2.7%	1.38 [1.05, 1.81]
Alpert et al 2020	129	421	1272	5135	2.9%	1.24 [1.06, 1.44]
Arslan et al 2021	14	41	45	672	2.2%	5.10 [3.06, 8.49]
Azarkar et al 2021	8	11	56	353	2.4%	4.58 [2.97, 7.08]
Baker 2021	10	33	71	283	2.1%	1.21 [0.69, 2.10]
Benelli 2020	9	33	63	378	2.0%	1.64 [0.90, 2.98]
Bennet et al 2021	233	747	1242	19042	3.0%	4.78 [4.24, 5.39]
Bernard et al 2021	2047	5722	13057	83329	3.0%	2.28 [2.20, 2.37]
Bhargava et al 2021	21	46	151	519	2.6%	1.57 [1.11, 2.21]
Borobia 2020	139	385	321	1841	2.9%	2.07 [1.75, 2.44]
Carmine Pinto et al 2020	47	138	283	1088	2.8%	1.31 [1.02, 1.69]
Chai et al 2021	49	166	44	498	2.6%	3.34 [2.31, 4.82]
Chen Fu et al 2021	80	233	819	3953	2.9%	1.66 [1.37, 2.00]
Costa et al 2020	2392	7406	65660	315410	3.0%	1.55 [1.50, 1.60]
Gude–Sampedro et al 2021	26	238	518	10216	2.5%	2.15 [1.48, 3.13]
Guo et al 2021	25	277	344	7649	2.5%	2.01 [1.36, 2.96]
Johoratnam–Hogan 2020	11	30	32	90	2.2%	1.03 [0.60, 1.78]
Katkat et al 2021	10	34	58	474	2.1%	2.40 [1.35, 4.27]
Kim et al 2021	54	569	171	7021	2.7%	3.90 [2.90, 5.23]
Kokturk et al 2021	20	76	47	1424	2.3%	7.97 [4.99, 12.75]
Liang et al 2021	23	109	229	2951	2.5%	2.72 [1.85, 3.99]
Lova Sun et al 2021	9	67	4	256	1.1%	8.60 [2.73, 27.06]
Lunski et al 2021	66	312	418	4833	2.8%	2.45 [1.94, 3.09]
Martinot et al 2021	32	109	83	491	2.6%	1.74 [1.22, 2.47]
Mirgh et al 2021	11	109	1	91	0.5%	9.18 [1.21, 69.79]
Miyashita et al 2020	37	334	518	5354	2.7%	1.14 [0.84, 1.57]
Nikpouraghdam 2020	1	17	238	2947	0.5%	0.73 [0.11, 4.90]
Péron et al 2021	43	108	54	193	2.6%	1.42 [1.03, 1.97]
Poli et al 2021	44	141	156	950	2.7%	1.90 [1.43, 2.52]
Qjubai Li et al 2020	18	65	191	1794	2.5%	2.60 [1.72, 3.94]
Reddy et al 2021	3	23	162	4471	1.2%	3.60 [1.24, 10.45]
Ricoca Peixoto 2020	47	603	455	19667	2.7%	3.37 [2.52, 4.50]
Rossi 2021	44	301	173	2352	2.7%	1.99 [1.46, 2.71]
Rugge et al 2020	106	723	385	8552	2.9%	3.26 [2.66, 3.98]
Sahingoz–Erdal et al 2021	17	71	68	4418	2.3%	15.56 [9.66, 25.06]
Segura et al 2021	250	729	449	770	3.0%	0.59 [0.52, 0.66]
Sorouri et al 2020	27	53	17	106	2.2%	3.18 [1.91, 5.29]
Stroppa 2020	9	25	5	31	1.4%	2.23 [0.86, 5.82]
Vergara et al 2021	25	49	313	1000	2.7%	1.63 [1.22, 2.18]
Vila–Corcoles et al 2021	23	67	101	469	2.5%	1.59 [1.10, 2.32]
Zhang et al 2022	125	824	2367	35534	2.9%	2.28 [1.93, 2.69]
Zhou et al 2021	12	103	9	206	1.6%	2.67 [1.16, 6.12]
Total (95% CI)		21599		557053	100.0%	2.26 [1.94, 2.62]
Total events	6326		90753			

Heterogeneity: Tau² = 0.20; Chi² = 1167.39, df = 41 (P < 0.00001); I² = 96%
Test for overall effect: Z = 10.60 (P < 0.00001)

Fig. 3 Forest plot illustrating the mortality of patients with cancer/non-cancer and SARS-CoV-2 infection

in the Asian continent (RR = 2.92, CI: 2.42—3.53) and with the lowest in the European Continent (RR = 2.21, 95% CI: 1.69–2.89, $p < 0.001$). No noticeable publication bias and obvious asymmetry was observed among the included studies (Supplementary Fig. S3 and S5). We found significant heterogeneity in this study results as seen in Fig. 3 (df = 41, $I^2 = 96\%$, $p < 0.001$). Sensitivity analyses were conducted by subtracting each of the studies. No significant change was observed in the analysis results.

ICU admission rates in SARS-CoV-2 infected cancer and non-cancer patients

ICU admission rates of a total of 22,671 SARS-CoV-2 infected cancer patients and 532,161 non-cancer patients were analyzed from 22 eligible studies (Alpert et al. 2021; Benelli et al. 2020; Bergman et al. 2021; Bernard et al. 2021; Pinto et al. 2020; Fu et al. 2021; Costa et al. 2021; Görgülü et al. 2020; Gude-Sampedro et al. 2021; Guo et al. 2021; Joharatnam-Hogan et al. 2020; Sun et al. 2021; Lunski et al. 2021; Martinot et al. 2021; Mirgh et al. 2021; Miyashita et al. 2020; Péron et al. 2021; Li et al. 2020a, b; Ricoca Peixoto et al. 2020; Rugge et al. 2020; Shahidsales et al. 2021; Sorouri et al. 2020). The rate of ICU admission in patients with cancer was significantly higher than in individuals without cancer (RR = 1.45, 95% CI: 1.28–1.64, $p < 0.001$; heterogeneity: df = 21, $I^2 = 87\%$, $p < 0.001$) (Fig. 5). It was determined that there was no publication bias according to the symmetry of the funnel plot and Egger's linear regression test (Supplementary Fig. S4). ICU admission in cancer patients infected with SARS-CoV-2 varies between continents, with the highest ICU admission rate in the Asian

Study or Subgroup	Cancer Events	Total	Non-Cancer Events	Total	Weight	Risk Ratio M-H, Random, 95% CI
1.1.1 Asia						
Azarkar et al 2021	8	11	56	353	2.4%	4.58 [2.97, 7.08]
Chai et al 2021	49	166	44	498	2.6%	3.34 [2.31, 4.82]
Guo et al 2021	25	277	344	7649	2.5%	2.01 [1.36, 2.96]
Kim et al 2021	54	569	171	7021	2.7%	3.90 [2.90, 5.23]
Liang et al 2021	23	109	229	2951	2.5%	2.72 [1.85, 3.99]
Mirgh et al 2021	11	109	1	91	0.5%	9.18 [1.21, 69.79]
Nikpouraghdam 2020	1	17	238	2947	0.5%	0.73 [0.11, 4.90]
Qjubai Li et al 2020	18	65	191	1794	2.5%	2.60 [1.72, 3.94]
Reddy et al 2021	3	23	162	4471	1.2%	3.60 [1.24, 10.45]
Sorouri et al 2020	27	53	17	106	2.2%	3.18 [1.91, 5.29]
Zhang et al 2022	125	824	2367	35534	2.9%	2.28 [1.93, 2.69]
Zhou et al 2021	12	103	9	206	1.6%	2.67 [1.16, 6.12]
Subtotal (95% CI)		2326		63621	24.0%	2.92 [2.42, 3.53]
Total events	356		3829			
Heterogeneity: Tau² = 0.05; Chi² = 23.25, df = 11 (P = 0.02); I² = 53%						
Test for overall effect: Z = 11.09 (P < 0.00001)						
1.1.2 Europe						
Akhtar et al 2021	30	51	103	242	2.7%	1.38 [1.05, 1.81]
Arslan et al 2021	14	41	45	672	2.2%	5.10 [3.06, 8.49]
Baker 2021	10	33	71	283	2.1%	1.21 [0.69, 2.10]
Benelli 2020	9	33	63	378	2.0%	1.64 [0.90, 2.98]
Bennet et al 2021	233	747	1243	19042	3.0%	4.78 [4.24, 5.38]
Bernard et al 2021	2047	5722	13057	83329	3.0%	2.28 [2.20, 2.37]
Borobia 2020	139	385	321	1841	2.9%	2.07 [1.75, 2.44]
Carmine Pinto et al 2020	47	138	283	1088	2.8%	1.31 [1.02, 1.69]
Gude-Sampedro et al 2021	26	238	518	10216	2.5%	2.15 [1.48, 3.13]
Johoratnam-Hogan 2020	11	30	32	90	2.2%	1.03 [0.60, 1.78]
Katkat et al 2021	10	34	58	474	2.1%	2.40 [1.35, 4.27]
Kokturk et al 2021	20	76	47	1424	2.3%	7.97 [4.99, 12.75]
Martinot et al 2021	32	109	83	491	2.6%	1.74 [1.22, 2.47]
Péron et al 2021	43	108	54	193	2.6%	1.42 [1.03, 1.97]
Poli et al 2021	44	141	156	950	2.7%	1.90 [1.43, 2.52]
Ricoca Peixoto 2020	47	603	455	19667	2.7%	3.37 [2.52, 4.50]
Rossi 2021	44	301	173	2352	2.7%	1.99 [1.46, 2.71]
Rugge et al 2020	106	723	385	8552	2.9%	3.26 [2.66, 3.98]
Sahingoz-Erdal et al 2021	17	71	68	4418	2.3%	15.56 [9.66, 25.06]
Segura et al 2021	250	729	449	770	3.0%	0.59 [0.52, 0.66]
Stroppa 2020	9	25	5	31	1.4%	2.23 [0.86, 5.82]
Vergara et al 2021	25	49	313	1000	2.7%	1.63 [1.22, 2.18]
Vila-Corcoles et al 2021	23	67	101	469	2.5%	1.59 [1.10, 2.32]
Subtotal (95% CI)		10454		157972	58.0%	2.21 [1.69, 2.89]
Total events	3236		18083			
Heterogeneity: Tau² = 0.39; Chi² = 846.73, df = 22 (P < 0.00001); I² = 97%						
Test for overall effect: Z = 5.80 (P < 0.00001)						
1.1.3 America						
Alpert et al 2020	129	421	1272	5135	2.9%	1.24 [1.06, 1.44]
Bhargava et al 2021	21	46	151	519	2.6%	1.57 [1.11, 2.21]
Chen Fu et al 2021	80	233	819	3953	2.9%	1.66 [1.37, 2.00]
Costa et al 2020	2392	7406	65660	315410	3.0%	1.55 [1.50, 1.60]
Lova Sun et al 2021	9	67	4	256	1.1%	8.60 [2.73, 27.06]
Lunski et al 2021	66	312	418	4833	2.8%	2.45 [1.94, 3.09]
Miyashita et al 2020	37	334	518	5354	2.7%	1.14 [0.84, 1.57]
Subtotal (95% CI)		8819		335460	18.0%	1.61 [1.35, 1.93]
Total events	2734		68842			
Heterogeneity: Tau² = 0.04; Chi² = 35.89, df = 6 (P < 0.00001); I² = 83%						
Test for overall effect: Z = 5.29 (P < 0.00001)						
Total (95% CI)		21599		557053	100.0%	2.26 [1.94, 2.62]
Total events	6326		90754			
Heterogeneity: Tau² = 0.20; Chi² = 1167.02, df = 41 (P < 0.00001); I² = 96%						
Test for overall effect: Z = 10.60 (P < 0.00001)						
Test for subgroup differences: Chi² = 20.06, df = 2 (P < 0.0001), I² = 90.0%						

Favours [experimental] Favours [control]
0.01 0.1 1 10 100

Fig. 4 Forest plot for region subgroup analysis of the cancer mortality of patients with cancer/non cancer in all SARS-CoV-2 infected participants

continent (RR = 2.26, CI: 1.80–2.83) and with the lowest in the European Continent (RR = 1.13, 95% CI: 0.86–1.48, $p < 0.001$) with no publication bias (Supplementary Fig. S1 and S6). Although there is a significant heterogeneity in Europe and America (df = 8, $I^2 = 78\%$, $p < 0.001$; df = 5, $I^2 = 86\%$, $p < 0.001$, respectively), no significant

Study or Subgroup	Cancer Events	Total	Non–Cancer Events	Total	Weight	Risk Ratio IV, Random, 95% CI	Risk Ratio IV, Random, 95% CI
Alpert et al 2020	82	421	913	5135	6.7%	1.10 [0.89, 1.34]	
Benelli 2020	2	33	26	378	0.7%	0.88 [0.22, 3.55]	
Bergman et al 2021	304	5515	2190	63060	7.6%	1.59 [1.41, 1.78]	
Bernard et al 2021	875	5722	13655	83329	8.0%	0.93 [0.88, 0.99]	
Carmine Pinto et al 2020	14	138	73	1088	3.2%	1.51 [0.88, 2.60]	
Chen Fu et al 2021	45	233	449	3953	5.9%	1.70 [1.29, 2.24]	
Costa et al 2020	3159	7406	113481	315410	8.1%	1.19 [1.15, 1.22]	
Gorgulu et al 2020	27	75	85	408	4.9%	1.73 [1.21, 2.47]	
Gude–Sampedro et al 2021	7	238	277	10216	2.1%	1.08 [0.52, 2.27]	
Guo et al 2021	30	277	314	7649	4.9%	2.64 [1.85, 3.76]	
Johoratnam–Hogan 2020	11	30	36	90	3.3%	0.92 [0.54, 1.56]	
Lova Sun et al 2021	17	67	30	256	3.3%	2.17 [1.27, 3.68]	
Lunski et al 2021	39	312	404	4833	5.5%	1.50 [1.10, 2.03]	
Martinot et al 2021	26	109	127	491	4.8%	0.92 [0.64, 1.33]	
Mirgh et al 2021	34	109	16	91	3.4%	1.77 [1.05, 3.00]	
Miyashita et al 2020	37	334	314	5354	5.3%	1.89 [1.37, 2.61]	
Péron et al 2021	10	108	35	193	2.5%	0.51 [0.26, 0.99]	
Qjubai Li et al 2020	7	65	78	1794	2.2%	2.48 [1.19, 5.15]	
Ricoca Peixoto 2020	22	611	239	19682	4.2%	2.97 [1.93, 4.55]	
Rugge et al 2020	54	723	531	8552	5.9%	1.20 [0.92, 1.57]	
Soodabeh Shahidsales et al 2021	22	92	14	93	2.8%	1.59 [0.87, 2.91]	
Sorouri et al 2020	29	53	28	106	4.5%	2.07 [1.39, 3.09]	
Total (95% CI)		**22671**		**532161**	**100.0%**	**1.45 [1.28, 1.64]**	
Total events	4853		133315				

Heterogeneity: Tau² = 0.05; Chi² = 167.47, df = 21 (P < 0.00001); I² = 87%
Test for overall effect: Z = 5.76 (P < 0.00001)

Favours [experimental]   Favours [control]
0.01   0.1   1   10   100

Fig. 5 Forest plot illustrating the ICU admission of patients with cancer/non-cancer in all SARS-CoV-2 infected participants

heterogeneity was observed in the Asian continent (df = 3, $I^2 = 0\%$, $p = 0.61$).

Discussion

It is a well-known fact that the incidence of cancer continues to increase rapidly worldwide, with lifestyle changes and environmental factors such as poor nutrition, polluted air, obesity, and sedentary lifestyle (Sung et al. 2021). Cancer patients have been severely affected by the outbreak of the COVID-19 pandemic caused by the SARS-CoV-2 virus. Studies with COVID-19 and cancer patients have reported that cancer is a risk factor that can lead to adverse clinical outcomes for SARS-CoV-2 infected cancer patients (Desai et al. 2020; Serraino 2020). However, in several studies, it was revealed that there was no significant difference in cancer and non-cancer populations in terms of mortality rates of COVID-19 (Liu et al. 2020; Spezzani et al. 2020; Barlesi et al. 2020). In another study conducted in France, it was reported that serious events in breast cancer patients were proximate to the general population. It has been stated that the reason for this situation is the stricter social distance procedures in terms of the location of cancer patients (Vuagnat et al. 2020). In addition to all these, in meta-analyses conducted on relatively small samples to our studies evaluating mortality, incidence and ICU hospitalization rates in cancer and non-cancer groups, it was reported that both mortality and ICU hospitalization rates of cancer patients were higher

than non-cancer patients (Giannakoulis et al. 2020; Yang et al. 2021; Salunke et al. 2020). Therefore, a more comprehensive meta-analysis is required to perform for determine the relationship between cancer and COVID-19 in larger geographies and samples.

A total of 58 papers were included in this systematic review and meta-analysis. 709,908 SARS-CoV-2 infected participants worldwide were systematically analyzed and a meta-analysis was performed. The incidence of cancer was estimated in all SARS-CoV-2 infected patients (8%, 95% CI: 8–9%). We concluded that this result is much higher than the rate of approximately 2% in the general population (Bray et al. 2018). However, cancer appeared to be an important risk factor for mortality in SARS-CoV-2 infected patients (RR = 2.26, 95% CI: 1.94–2.62, $P < 0.001$). In addition, the ICU admission rate was significantly higher in patients with cancer than in patients without cancer (RR = 1.45, 95% CI: 1.28–1.64, $p < 0.001$). The risk of infection in cancer patients differs according to factors such as genetic predisposition, physical condition, ethnicity, nutritional status, age and sex of individuals (Zhang et al. 2020). Thus, virus can more easily enter cells in cancer patients (Zhang et al. 2020; Dai et al. 2020; Ma et al. 2020). Moreover, it can make the immune system weak in cancer patients even more dysfunctional (Zhang et al. 2020; Dai et al. 2020). Besides, patients with cancer must visit the hospital on a routine basis to have their treatment. This may be a factor that directly increases the risk of SARS-CoV-2 infection.

Previous studies (Giannakoulis et al. 2020; Gao et al. 2020; Salunke et al. 2020; Yang et al. 2021) were carried out with relatively smaller samples compared to our study. Studies on COVID-19 are constantly increasing cumulatively. Our study included a substantial sample covering large geographic regions and many countries. There were studies with duplicate samples. To avoid duplication of sample sources, we included only studies with the largest sample size. We evaluated the quality of the included studies using the NOS. Studies with a score of six or more were considered high-quality studies. Sensitivity analysis, a method that excludes each study separately, was performed. There was no noticeable difference in the analysis results. These findings showed that the study was stable and robust.

Limitations

There were some limitations to this research. The most of data in the included studies were from hospital-based studies. In this regard, there may be inherent biases, particularly in patient selection, medical and surgical treatment regimens, and loss of follow-up of patients. In addition, most SARS-CoV-2 infected cancer patients without hospitalization may have been excluded. Because most of the included studies did not have information on the effect of treatment or chemotherapy on ICU admission and / or mortality, their impact could not be evaluated. In addition to all these, the inability to compare cancer patients without COVID-19 with cancer patients suffering from COVID-19, which can be resulting in a potential bias in the study, was another important limitation of the study. A high level of heterogeneity was detected in most of the results, including the incidence analysis. Furthermore, although we performed subgroup analysis and sensitivity analysis, these results were not sufficient to explain the source of heterogeneity. However, our study included large sample sizes in a wide range of countries and populations across several geographies. This may indicate that healthcare, lifestyles, ethnic differences, treatment types and procedures may have increased or decreased susceptibility to cancer or SARS-CoV-2 infection. Importantly, the COVID-19 pandemic was managed diversely in different nations, as were the techniques adopted to control and prevent to SARS-CoV-2 infection. All these reasons could potentially have influenced the high level of heterogeneity. Finally, in all countries, further improvement, and development of community-based registries, where hospital-based information is collected, may also allow meta-analyses to be conducted with larger populations.

Conclusions

To date, the pandemic has caused the loss of many people. But it should be kept in mind that cancer is at least as deadly as COVID-19. As a result, cancer was an important comorbidity and risk factor for all COVID-19 patients, and SARS-CoV-2 infection could result in severe and even fatal events in cancer patients. The results of the current systematic review and meta-analysis show that cancer patients with SARS-CoV-2 infection have higher ICU admission and higher mortality rates. The most important advantage of this study was that the sample size was very large, and it represented and covered a wide range of geographies. This study emphasized the importance of managing patients with comorbidities, especially cancer, during the COVID-19 pandemic. In addition, cancer patients may have more hospital visits due to multi-stage treatment in cancer. Thus, cancer patients may become prone and susceptible to COVID-19. So, the frequency of follow-up of cancer patients could be reduced during periods when the rate of the epidemic was high, and if possible, treatments could be postponed for a while. Also, and importantly, healthcare professionals should be vigilant for cancer patients, especially COVID-19 period, individualized treatment plans should be devised to avoid disease progression.

Declarations

Competing interests The authors declare no competing interests.

Conflict of interest The authors declare no potential conflicts of interest.

References

Adejumo OA, Ogunniyan T, Adesola S, Gordon I, Oluwadun OB, Oladokun OD et al (2021) Clinical presentation of

COVID-19-positive and-negative patients in Lagos Nigeria: a comparative study. Niger Postgrad Med J 28:75. https://doi.org/10.4103/npmj.npmj_547_21

Akhtar Z, Gallagher MM, Yap YG, Leung LW, Elbatran AI, Madden B et al (2021) Prolonged QT predicts prognosis in COVID-19. Pacing Clin Electrophysiol 44:875–882. https://doi.org/10.1111/pace.14232

Alpert N, Rapp JL, Marcellino B, Lieberman-Cribbin W, Flores R, Taioli E (2021) Clinical course of cancer patients with COVID-19: a retrospective cohort study. JNCI Cancer. https://doi.org/10.1093/jncics/pkaa085

Arslan Y, Dogan D, Ocal N, Koc A, Ayaz T, Ozkan R et al (2021) The boundaries between survival and nonsurvival at COVID-19: experience of tertiary care pandemic hospital. Int J Clin Pract 75:e14461. https://doi.org/10.1111/ijcp.14461

Azarkar Z, Salehiniya H, Kazemi T, Abbaszadeh H (2021) Epidemiological, imaging, laboratory, and clinical characteristics and factors related to mortality in patients with COVID-19: a single-center study. Osong Public Health Res Perspect. 12:169–176. https://doi.org/10.24171/j.phrp.2021.0012

Baker KF, Hanrath AT, van der Loeff IS, Tee SA, Capstick R, Marchitelli G et al (2021) COVID-19 management in a UK NHS foundation trust with a high consequence infectious diseases centre: a retrospective analysis. Med Sci 9:6. https://doi.org/10.3390/medsci9010006

Barlesi F, Foulon S, Bayle A, Gachot B, Pommeret F, Willekens C et al (2020) Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments. AACR Annual Meeting 2020 Online abstr.CT403:27–28.

Benelli G, Buscarini E, Canetta C, La Piana G, Merli G, Scartabellati A et al (2020) SARS-CoV-2 comorbidity network and outcome in hospitalized patients in Crema, Italy. MedRxiv. https://doi.org/10.1101/2020.04.14.20053090

Bennett KE, Mullooly M, O'Loughlin M, Fitzgerald M, O'Donnell J, O'Connor L et al (2021) Underlying conditions and risk of hospitalisation, ICU admission and mortality among those with COVID-19 in Ireland: a national surveillance study. Lancet Reg Health Eur 5:100097. https://doi.org/10.1016/j.lanepe.2021.100097

Bergman J, Ballin M, Nordström A, Nordström P (2021) Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study. Eur J Epidemiol 36:287–298. https://doi.org/10.1007/s10654-021-00732-w

Bernard A, Cottenet J, Bonniaud P, Piroth L, Arveux P, Tubert-Bitter P et al (2021) Comparison of cancer patients to non-cancer patients among COVID-19 inpatients at a national level. Cancers 13:1436. https://doi.org/10.3390/cancers13061436

Bhargava A, Szpunar SM, Sharma M, Fukushima EA, Hoshi S, Levine M et al (2021) Clinical features and risk factors for in-hospital mortality from COVID-19 infection at a tertiary care medical center, at the onset of the US COVID-19 pandemic. J Intensive Care Med 36:711–718. https://doi.org/10.1177/08850666211001799

Borobia AM, Carcas AJ, Arnalich F, Alvarez-Sala R, Montserrat J, Quintana M et al (2020) A cohort of patients with COVID-19 in a major teaching hospital in Europe. MedRxiv. https://doi.org/10.1101/2020.04.29.20080853

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

Cavanna L, Citterio C, Toscani I, Franco C, Magnacavallo A, Caprioli S et al (2020) Cancer patients with COVID-19: a retrospective study of 51 patients in the district of Piacenza, northern Italy. Future Sci OA. 7:FSO645. https://doi.org/10.2144/fsoa-2020-0157

Chai C, Feng X, Lu M, Li S, Chen K, Wang H et al (2021) One-year mortality and consequences of COVID-19 in cancer patients: a cohort study. IUBMB Life 73:1244–1256. https://doi.org/10.1002/iub.2536

Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T et al (2020) Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep 69:382–386. https://doi.org/10.15585/mmwr.mm6913e2

Chudasama YV, Zaccardi F, Gillies CL, Razieh C, Yates T, Kloecker DE et al (2021) Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the UK. BMC Infect Dis 21:1–12. https://doi.org/10.1186/s12879-021-06600-y

Costa GJ, de Azevedo CRAS, Júnior JIC, Bergmann A, Thuler LCS (2021) Higher severity and risk of in-hospital mortality for COVID-19 patients with cancer during the year 2020 in Brazil: a countrywide analysis of secondary data. Cancer 127:4240–4248. https://doi.org/10.1002/cncr.33832

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z et al (2020) Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 10:783–791. https://doi.org/10.1158/2159-8290.CD-20-0422

Desai A, Sachdeva S, Parekh T, Desai R (2020) COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol 6:557–559. https://doi.org/10.1200/GO.20.00097

Duanmu YY, Brown IP, Gibb WR, Singh J, Matheson LW, Blomkalns AL et al (2020) Characteristics of emergency department patients with COVID-19 at a single site in northern California: clinical observations and public health implications. Acad Emerg Med 27:505–509. https://doi.org/10.1111/acem.14003

Erdal GS, Polat O, Erdem GU, Korkusuz R, Hindilerden F, Yilmaz M et al (2021) The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study. Int J Clin Oncol 26:826–834. https://doi.org/10.1007/s10147-021-01863-6

Espinosa OA, Zanetti ADS, Antunes EF, Longhi FG, Matos TA, Battaglini PF (2020) Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and metaanalysis. Rev Inst Med Trop Sao Paulo 62:e43. https://doi.org/10.1590/S1678-9946202062043

Fu C, Stoeckle JH, Masri L, Pandey A, Cao M, Littman D et al (2021) COVID-19 outcomes in hospitalized patients with active cancer: experiences from a major New York city health care system. Cancer 127:3466–3475. https://doi.org/10.1002/cncr.33657

Gao Y, Liu M, Shi S, Chen Y, Sun Y, Chen J et al (2020) Cancer is associated with the severity and mortality of patients with COVID-19: a systematic review and meta-analysis. MedRxiv. https://doi.org/10.1101/2020.05.01.20087031

Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T et al (2020) The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis 39:1011–1019. https://doi.org/10.1007/s10096-020-03874-z

Giannakoulis VG, Papoutsi E, Siempos II (2020) Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data. JCO Global Oncol 6:799–808. https://doi.org/10.1200/GO.20.00225

Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R (2020) Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the province of Reggio Emilia, Italy. PLoS ONE 15:e0238281. https://doi.org/10.1371/journal.pone.0238281

GLOBOCAN (Globoal Cancer Observatory) (2022) Cancer Tomorrow. Estimated Number of New Cases and Deaths from 2020 to 2040, Both sexes, Age [0–85+]. Accessed on: https://gco.iarc.fr/tomorrow/en/dataviz/bars?mode=population&key=total&show_bar_mode_prop=1&types=1. Accessed 24 April 2022

Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossow J, da Silva J et al (2020) Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 – Georgia, March 2020. MMWR Morb Mortal Wkly Rep 69:545–550. https://doi.org/10.15585/mmwr.mm6918e1

Görgülü Ö, Duyan M (2020) Effects of comorbid factors on prognosis of three different geriatric groups with COVID-19 diagnosis. SN Compr Clin Med 2:2583–2594. https://doi.org/10.1007/s42399-020-00645-x

Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A et al (2020) Clinical characteristics of COVID-19 in New York city. N Engl J Med 382:2372–2374. https://doi.org/10.1056/NEJMc2010419

Gude-Sampedro F, Fernández-Merino C, Ferreiro L, Lado-Baleato Ó, Espasandín-Domínguez J, Hervada X et al (2021) Development and validation of a prognostic model based on comorbidities to predict COVID-19 severity: a population-based study. Inter J of Epidemiol 50:64–74. https://doi.org/10.1093/ije/dyaa209

Guo D, Wang H, Zhu Q, Yuan Y (2021) Clinical Characteristics of cancer patients with COVID-19: a retrospective multicentric study in 19 hospitals within Hubei, China. Front Med 8:614057. https://doi.org/10.3389/fmed.2021.614057

Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557

The jamovi project (2021) jamovi (Version 2.3.3) [Computer Software]. Retrieved from https://www.jamovi.org.

Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W et al (2020) Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 12:372. https://doi.org/10.3390/v12040372

Joharatnam-Hogan N, Hochhauser D, Shiu K-K, Rush H, Crolley V, Butcher E et al (2020) Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer – a multi-centre north London experience. Ther Adv Med Oncol 12:1758835920956803. https://doi.org/10.1177/1758835920956803

Katkat F, Karahan S, Varol S, Kalyoncuoglu M, Okuyan E (2021) Mortality prediction with CHA2DS2-VASc CHA2DS2-VASc-HS and R2CHA2DS2-VASc score in patients hospitalized due to COVID-19. Eur Rev Med Pharmacol Sci 25:6767–6774. https://doi.org/10.26355/eurrev_202111_27121

Kim E, Kim YC, Park JY, Jung J, Lee JP, Kim H (2021) Evaluation of the prognosis of COVID-19 patients according to the presence of underlying diseases and drug treatment. Int J Environ Res Public Health 18:5342. https://doi.org/10.3390/ijerph18105342

Kokturk N, Babayigit C, Kul S, Cetinkaya PD, Nayci SA, Baris SA et al (2021) The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients. Respir Med 183:106433. https://doi.org/10.1016/j.rmed.2021.106433

Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB et al (2020a) COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 92:577–583. https://doi.org/10.1002/jmv.25757

Li Q, Chen L, Li Q, He W, Yu J, Chen L et al (2020b) Cancer increases risk of in-hospital death from COVID-19 in persons< 65 years and those not in complete remission. Leukemia 34:2384–2391. https://doi.org/10.1038/s41375-020-0986-7

Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y et al (2020) Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (nonepicentre): a nationwide analysis of China. Eur Respir J 55:2000562. https://doi.org/10.1183/13993003.00562-2020

Liang J, Jin G, Liu T, Wen J, Li G, Chen L et al (2021) Clinical characteristics and risk factors for mortality in cancer patients with COVID-19. Front Med 15:264–274. https://doi.org/10.1007/s11684-021-0845-6

Liberati A, Altman DG, Tetzla J, Mulrow C, Gotzsche PC et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100. https://doi.org/10.1016/j.jclinepi.2009.06.006

Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X (2020) COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med 17:519–527. https://doi.org/10.20892/j.issn.2095-3941.2020.0289

Lu H, Stratton CW, Tang YW (2020) Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol 92:401e1. https://doi.org/10.1002/jmv.25678

Lunski MJ, Burton J, Tawagi K, Maslov D, Simenson V, Barr D et al (2021) Multivariate mortality analyses in COVID-19: comparing patients with cancer and patients without cancer in Louisiana. Cancer 127:266–274. https://doi.org/10.1002/cncr.33243

Ma J, Yin J, Qian Y, Wu Y (2020) Clinical characteristics and prognosis in cancer patients with COVID-19: a single center's retrospective study. J Infect 81:318–356. https://doi.org/10.1016/j.jinf.2020.04.006

Martinot M, Eyriey M, Gravier S, Bonijoly T, Kayser D, Ion C et al (2021) Predictors of mortality, ICU hospitalization, and extrapulmonary complications in COVID-19 patients. Infect Dis Now 51:518–525. https://doi.org/10.1016/j.idnow.2021.07.002

Mirgh SP, Gokarn A, Rajendra A, More A, Kamtalwar S, Katti KS et al (2021) Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary cancer centre in India. Cancer Med 10:8777–8788. https://doi.org/10.1002/cam4.4379

Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D et al (2020) Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York city. Ann Oncol 31:1088–1089. https://doi.org/10.1016/j.annonc.2020.04.006

Nakamura S, Kanemasa Y, Atsuta Y, Fujiwara S, Tanaka M, Fukushima K et al (2021) Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan. Int J Clin Oncol 26:485–493. https://doi.org/10.1007/s10147-020-01837-0

Nikpouraghdam M, Jalali Farahani A, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H et al (2020) Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in Iran: a single center study. J Clin Virol 127:104378. https://doi.org/10.1016/j.jcv.2020.104378

Panda S, Roy S, Garg RK, Hui G, Gorard J, Bhutada M et al (2022) COVID-19 disease in hospitalized young adults in India and China: evaluation of risk factors predicting progression across two major ethnic groups. J Med Virol 94:272–278. https://doi.org/10.1002/jmv.27315

Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F et al (2020) COVID-19 diagnosis and management: a comprehensive review. J Intern Med 288:192–206. https://doi.org/10.1111/joim.13091

Pérez-Segura P, Paz-Cabezas M, Núñez-Gil IJ, Arroyo-Espliguero R, Eid CM, Romero R et al (2021) Prognostic factors at admission on patients with cancer and COVID-19: analysis of HOPE registry data. Med Clin 157:318–324. https://doi.org/10.1016/j.medcle.2021.02.010

Péron J, Dagonneau T, Conrad A, Pineau F, Calattini S, Freyer G et al (2021) COVID-19 presentation and outcomes among cancer patients: a matched case-control study. Cancers 13:5283. https://doi.org/10.3390/cancers13215283

Pinto C, Berselli A, Mangone L, Damato A, Iachetta F, Foracchia M et al (2020) SARS-CoV-2 positive hospitalized cancer patients during the Italian outbreak: the cohort study in Reggio Emilia. Biology 9:181. https://doi.org/10.3390/biology9080181

Poli D, Antonucci E, Ageno W, Prandoni P, Palareti G, Marcucci R (2022) Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre

observational START-COVID register. Intern Emerg Med 17:1013–1021. https://doi.org/10.1007/s11739-021-02891-w

ProMeta-3 professional statistical software for conducting meta-analysis (2015) It is based on ProMeta 2.1 deployed by Internovi in 2015. https://idostatistics.com/prometa3/

Reddy KP, Elagandula J, Patel S, Patidar R, Asati V, Shrivastav SP et al (2021) The impact of COVID-19 pandemic on cancer care in a tertiary care facility. South Asian J Cancer 10:32–35. https://doi.org/10.1055/s-0041-1731577

Regina J, Papadimitriou-Olivgeris M, Burger R, Filippidis P, Tschopp J, Desgranges F et al (2020) Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: an observational retrospective study. PLoS ONE 15:e0240781. https://doi.org/10.1371/journal.pone.0240781

Review Manager (RevMan) [Computer program]. Version 5.4 (2020) The Cochrane Collaboration. Available at revman.cochrane.org

Ricoca Peixoto V, Vieira A, Aguiar P, Sousa P, Carvalho C, Thomas D et al (2020) COVID-19: determinants of hospitalization, ICU and death among 20,293 reported cases in Portugal. Euro Surveill 26:2001059. https://doi.org/10.2807/1560-7917.ES.2021.26.33.2001059

Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C et al (2020) Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 382:970e1. https://doi.org/10.1056/NEJMc2001468

Rugge M, Zorzi M, Guzzinati S (2020) SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer. Nat Cancer 1:784–788. https://doi.org/10.1038/s43018-020-0104-9

Salunke AA, Nandy K, Pathak SK, Shah J, Kamani M, Kottakota V et al (2020) Impact of COVID-19 in cancer patients on severity of disease and fatal outcomes: a systematic review and meta-analysis. Diabetes Metab Syndr 14:1431–1437. https://doi.org/10.1016/j.dsx.2020.07.037

Sami R, Soltaninejad F, Amra B, Naderi Z, Haghjooy Javanmard S, Iraj B et al (2020) A one-year hospital-based prospective COVID-19 open-cohort in the eastern Mediterranean region: the khorshid COVID cohort (KCC) study. PLoS ONE 15:e0241537. https://doi.org/10.1371/journal.pone.0241537

Santorelli G, McCooe M, Sheldon TA, Wright J, Lawton T (2021) Ethnicity, pre-existing comorbidities, and outcomes of hospitalised patients with COVID-19. Wellcome Open Res. 6:32. https://doi.org/10.12688/wellcomeopenres.16580.2

Serraino D (2020) COVID-19 and cancer: looking for evidence. Eur J Surg Oncol 46:929–930. https://doi.org/10.1016/j.ejso.2020.05.002

Serraino D, Zucchetto A, Dal Maso L, Del Zotto S, Taboga F, Clagnan E et al (2021) Prevalence, determinants, and outcomes of SARS-COV-2 infection among cancer patients. A population-based study in northern Italy. Cancer Med 10:7781–7792. https://doi.org/10.1002/cam4.4271

Shahidsales S, Aledavood SA, Joudi M, Molaie F, Esmaily H et al (2021) COVID-19 in cancer patients may be presented by atypical symptoms and higher mortality rate, a case-controlled study from Iran. Cancer Rep 4:e1378. https://doi.org/10.1002/cnr2.1378

Sorouri M, Kasaeian A, Mojtabavi H, Radmard AR, Kolahdoozan S, Anushiravani A et al (2020) Clinical characteristics, outcomes, and risk factors for mortality in hospitalized patients with COVID-19 and cancer history: a propensity score-matched study. Infect Agents Cancer 15:1–11. https://doi.org/10.1186/s13027-020-00339-y

Spezzani V, Piunno A, Iselin HU (2020) Benign COVID-19 in an immunocompromised cancer patient – the case of a married couple. Swiss Med Wkly 150:w20246. https://doi.org/10.4414/smw.2020.20246

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. Eur J Epidemiol 25:603–605. https://doi.org/10.1007/s10654-010-9491-z

Stroppa EM, Toscani I, Citterio C, Anselmi E, Zaffignani E, Codeluppi M et al (2020) Coronavirus disease-2019 in cancer patients. a report of the first 25 cancer patients in a western country (Italy). Future Oncol 16:1425–1432. https://doi.org/10.2217/fon-2020-0369

Sun L, Surya S, Le AN, Desai H, Doucette A, Gabriel P et al (2021) Rates of COVID-19–related outcomes in cancer compared with noncancer patients. JNCI Cancer Spectr. https://doi.org/10.1093/jncics/pkaa120

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Tehrani DM, Wang X, Rafique AM, Hayek SS, Herrmann J, Neilan TG et al (2021) Impact of cancer and cardiovascular disease on in-hospital outcomes of COVID-19 patients: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Cardio-Oncology 7:1–8. https://doi.org/10.1186/s40959-021-00113-y

Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z et al (2020) Characteristics of COVID-19 infection in Beijing. J Infect 80:401–406. https://doi.org/10.1016/j.jinf.2020.02.018

Vergara P, Rossi L, Biagi A, Falasconi G, Pannone L, Zanni A et al (2021) Role of comorbidities on the mortality in patients with SARS-CoV-2 infection: an Italian cohort study. Minerva Med. https://doi.org/10.23736/S0026-4806.21.07187-1

Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM et al (1998) The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51:1235–1241. https://doi.org/10.1016/s0895-4356(98)00131-0

Vila-Corcoles A, Satue-Gracia E, Vila-Rovira A, de Diego-Cabanes C, Forcadell-Peris MJ, Ochoa-Gondar O et al (2021) COVID19-related and all-cause mortality risk among middle-aged and older adults across the first epidemic wave of SARS-COV-2 infection: a population-based cohort study in southern Catalonia, Spain, March–June 2020. BMC Public Health 21:1–15. https://doi.org/10.1186/s12889-021-11879-2

Vuagnat P, Frelaut M, Ramtohul T, Basse C, Diakite S, Noret A et al (2020) COVID-19 in breast cancer patients: a cohort at the Institut Curie Hospitals in the Paris area. Breast Cancer Res 22:55. https://doi.org/10.1186/s13058-020-01293-8

WHO (2021) Weekly epidemiological update on COVID-19 - 20 July 2021 Edition 49. Accessed on: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---20-july-2021 Accessed 29 January 2022

WHO (2022) WHO Coronavirus Disease (COVID-19) Dashboard. Coronavirus disease (COVID-2019) situation reports, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports Accessed 01 May 2022

Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese center for disease control and prevention. JAMA 323:1239–1242. https://doi.org/10.1001/jama.2020.2648

Yang L, Chai P, Yu J, Fan X (2021) Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med 18:298. https://doi.org/10.20892/j.issn.2095-3941.2020.0559

Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R et al (2020) Clinical characteristics of COVID-19-infected cancer patients: a

retrospective case study in three hospitals within Wuhan, China. Ann Oncol 31:894–901. https://doi.org/10.1016/j.annonc.2020.03.296

Zhang H, Wu Y, He Y, Liu X, Liu M, Tang Y et al (2021) Age-related risk factors and complications of patients with COVID-19: a population-based retrospective study. Front Med 8:757459. https://doi.org/10.3389/fmed.2021.757459

Zhou Y, Yang Q, Ye J, Wu X, Hou X, Feng Y et al (2021) Clinical features and death risk factors in COVID-19 patients with cancer: a retrospective study. BMC Infect Dis 21:1–10. https://doi.org/10.1186/s12879-021-06495-9

Authors and Affiliations

Mehmet Emin Arayici[1] · **Nazlican Kipcak**[2] · **Ufuktan Kayacik**[3] · **Cansu Kelbat**[2] · **Deniz Keskin**[2] · **Muhammed Emin Kilicarslan**[2] · **Ahmet Veli Kilinc**[2] · **Sumeyye Kirgoz**[2] · **Anil Kirilmaz**[2] · **Melih Alihan Kizilkaya**[2] · **Irem Gaye Kizmaz**[2] · **Enes Berkin Kocak**[2] · **Enver Kochan**[2] · **Begum Kocpinar**[2] · **Fatmanur Kordon**[2] · **Batuhan Kurt**[2] · **Hulya Ellidokuz**[3,4]

Nazlican Kipcak
nazlicankipcak1@gmail.com

Ufuktan Kayacik
ufuktan.kayacik@ogr.deu.edu.tr

Cansu Kelbat
cansu.kelbat@ogr.deu.edu.tr

Deniz Keskin
denizkeskin2435@gmail.com

Muhammed Emin Kilicarslan
muhammedemin.kilicarslan@ogr.deu.edu.tr

Ahmet Veli Kilinc
hmtklnc67@gmail.com

Sumeyye Kirgoz
sumeyye.kirgoz@ogr.deu.edu.tr

Anil Kirilmaz
anil.kirilmaz@ogr.deu.edu.tr

Melih Alihan Kizilkaya
melihalihan-2001@hotmail.com

Irem Gaye Kizmaz
iremgaye.kizmaz@ogr.deu.edu.tr

Enes Berkin Kocak
enesberkin.kocak@ogr.deu.edu.tr

Enver Kochan
enver.kochan@ogr.deu.edu.tr

Begum Kocpinar
kocpinarbegum@gmail.com

Fatmanur Kordon
2000fatmanurkordon@gmail.com

Batuhan Kurt
batuhan.kurt@ogr.deu.edu.tr

Hulya Ellidokuz
hulyazeyda@gmail.com

[1] Department of Preventive Oncology, Institute of Health Sciences, Dokuz Eylul University, 15 July Medicine and Art Campus, Inciralti-Balcova 35340, Izmir, Turkey

[2] Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey

[3] Department of Biostatistics and Medical Informatics, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey

[4] Department of Preventive Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey